People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Other Technology, Biotechnology, Other, Healthtech, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BetterUP, Inc. | — | Other Technology | Series D+ | $486.2M | $2.1M | 2021 |
| Vineti, Inc. | — | Biotechnology | Series C | $115.7M | $2.8B | 2018 |
| Verge Analytics, Inc. | — | Biotechnology | Series C | $85.0M | $2.4B | 2021 |
| Brightline, Inc. | — | Other | Series B | $34.4M | $108.4M | 2020 |
| OODA Health, Inc. | — | Healthtech | Series B | $30.5M | $755.9M | 2018 |
| Calibrate Health NewCo, LLC | — | Healthtech | Series B | $29.1M | $245.1M | 2023 |
| Salvo Health, Inc. | — | Healthtech | Series B | $24.5M | $40.0M | 2024 |
| Oration PBC | — | Other Health Care | Series A | $10.8M | $218.7M | 2014 |
| Aiwa Health, Inc. | — | Healthtech | Series A | $10.7M | $71.9M | 2023 |
| Myshape Inc | — | Other | Series A | $10.6M | $159.8M | 2009 |
Emily Melton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Emily Melton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ann Lamont | 2 | 9 |
| Giovanni Colella | 2 | 4 |
| Nina Kjellson | 1 | 11 |
| Risa Stack | 1 | 9 |
| Barry Schuler | 1 | 9 |
| Seth Cohen | 1 | 7 |
| Rowan Chapman | 1 | 7 |
| Will Kohler | 1 | 6 |
| Eli Casdin | 1 | 6 |
| Ben Boyer | 1 | 6 |
| Doug Pepper | 1 | 5 |
| Andrew Allen | 1 | 4 |
| Michael Pellini | 1 | 4 |
| Kira Wampler | 1 | 4 |
| Chris Krueger | 1 | 3 |
| John Kontor | 1 | 2 |
| Mike Reisler | 1 | 2 |
| Jeffrey Glueck | 1 | 2 |
| Richard Clayton | 1 | 2 |
| Kevin Rubin | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.